TIMP2 and acute kidney injury: Numerous studies have explored the utilization of early biomarkers of AKI, such as NGAL and the recent combination of tissue inhibitor of metalloproteinase-2 and urine insulin-like growth factor-binding protein 7, in critically ill patients during the last decade [53–59].